New immune therapy shows promise in kidney cancer

June 4, 2012

An antibody that helps a person's own immune system battle cancer cells shows increasing promise in reducing tumors in patients with advanced kidney cancer, according to researchers at Beth Israel Deaconess Medical Center.

The results of an expanded Phase 1 trial presented at the American Society of Clinical Oncology's annual conference in Chicago, showed that some patients treated with a fully developed by had a positive response to the effort by the agent, BMS-936558, to prolong the immune system's efforts to fight off without some of the debilitating side effects common to earlier immunotherapies.

The presentation by David F. McDermott, MD, Director of Biologic Therapy Program at the Beth Israel Deaconess Medical Center Cancer Center and an Assistant Professor of Medicine at Harvard Medical School, highlights one of two key efforts underway to use the body's own disease-fighting tools against cancer.

Separate work by David Avigan MD, Director of BIDMC's Blood/ Program, focuses on developing a personalized vaccine, compromised of the patient's tumor and agents, to battle .

have the ability to trick the immune system, the body's self-defense mechanism, which is designed to ward off infections. Immune therapy such as and vaccines is designed to reeducate the body to recognized cancer as an invader.

"We've known for a long time that in certain cases the immune system can be boosted in a way that can create remissions" of like leukemia and lymphoma, says McDermott. "We've been trying to create the same long term results in solid tumors, which is more difficult."

In this trial, the antibody was designed to block the Programmed Death (PD)-1 inhibitory receptor expressed by activated T cells. PD-1 acts a natural shut off valve for T cells. By blocking its action, these cells can be revived to fight cancer. In the initial portion of the trial, the agent showed "promising" activity in patients with various solid tumors, including metastatic renal cell carcinoma, melanoma and lung cancer.

In an expanded trial, patients received up 10 mg/kg of an intravenous treatment twice weekly, followed by 1 mg/kg. Patients received up to 12 cycles of treatment until either progressive disease, unacceptable toxicity or a complete response was detected.

"These antibodies were developed based on an understanding of how the immune system is not well designed to fight cancer," says McDermott. "Your immune system is in place to help fight off infections. So when you have a viral infection, it will turn on in response to that infection and once it's controlled will shut down. The shut off valves, like PD-1, are actually stronger the pathways that turn on the immune system and this makes cancer difficult to control. The new PD-1 blocking antibody prevents this natural shutoff and allows T-cells to recognize and kill tumors."

McDermott noted that unlike current immunotherapies using interleukin-2, patients do not need to be hospitalized and suffer far less significant side effects such as skin rash or nausea.

"We realized that we could this drug at the highest doses without developing many significant or too dangerous side effects," says McDermott. "Once we realized the drug was relatively safe to give, we expanded into larger numbers of patients who seem to be benefiting early on from this treatment."

McDermott cautions that it is too early in a Phase I trial, designed principally to test side effects and the best dosage and schedule of treatment, to draw sweeping conclusions from the results.

"We have seen about 30 percent of the patients with kidney cancer have major responses to this line of treatment. A similar 30 percent of melanoma patients have had major response to treatment and there are much more melanoma patients in this study than kidney cancer patients. And maybe 20 percent or so of with lung cancer have had major benefit."

Explore further: Cancer therapy that boosts immune system ready for wider testing

Related Stories

Cancer therapy that boosts immune system ready for wider testing

June 2, 2012
Two clinical trials led by Johns Hopkins Kimmel Cancer Center researchers in collaboration with other medical centers, testing experimental drugs aimed at restoring the immune system's ability to spot and attack cancer, have ...

Combination antibody therapy shows promise in metastatic melanoma

June 4, 2011
(Medical Xpress) -- A duo of drugs, each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to ...

Bright future ahead for antibody cancer therapy

March 15, 2012
Antibodies, once touted as the "magic bullets" of cancer care, are now fulfilling that promise and more advances are on the way, say cancer researchers at the Georgetown Lombardi Comprehensive Cancer Center

Cancer-seeking 'smart bombs' target kidney cancer cells

June 6, 2011
Researchers are halting kidney cancer with a novel form of radioimmunotherapy that zeroes in on antigens associated with renal cell carcinoma. Patients with progressive kidney cancer receiving up to three doses of the therapy ...

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.